Canonical text (the exact bytes fingerprinted)

TRUVACE RECORD VERSION
record: TRV-2026-1436
version: 1
kind: certified
reason: Certified into the record
timestamp: 2026-10-15T10:42:39.897439Z
status: published
lens: trace
sector: health
headline: Artificial Intelligence applied to surgical pathology in the management of cutaneous melanoma
dek: Surgical pathology remains the cornerstone for the diagnosis, staging and prognostic stratification of cutaneous melanoma. The emergence of digital pathology and artificial intelligence (AI), notably deep learning, is transforming this field. Convolutional neural networks trained on large repositories of digitised histological slides demonstrate diagnostic capabilities comparable, and in specific tasks superior, to board-certified dermatopathologists. Current applications encompass the automated classification o…
gain_title: Convolutional neural networks trained on digitised slides can classify melanocytic lesions and infer molecular features such as BRAF status from routine stained slides, with performance comparable to dermatopathologists.
problem_title: Use of pathology AI in melanoma is held back by dataset bias, inconsistent slide-imaging workflows between laboratories, limited model interpretability, and unresolved medico-legal accountability.
trace_subject: AI-assisted pathology diagnosis and prognosis of cutaneous melanoma
gain_reading: Convolutional neural networks trained on digitised slides can classify melanocytic lesions and infer molecular features such as BRAF status from routine stained slides, with performance comparable to dermatopathologists.
gain_evidence: demonstrate diagnostic capabilities comparable, and in specific tasks superior, to board-certified dermatopathologists | predicting underlying molecular alterations, including BRAF mutational status
problem_reading: Use of pathology AI in melanoma is held back by dataset bias, inconsistent slide-imaging workflows between laboratories, limited model interpretability, and unresolved medico-legal accountability.
problem_evidence: Challenges remain, including dataset bias, inter-laboratory standardisation of whole slide imaging workflows, model interpretability, and medico-legal accountability.
quick_read: This review describes how digital pathology and deep learning are being applied to cutaneous melanoma. Neural networks trained on large collections of digitised histology slides can sort melanocytic lesions, including the hard distinction between benign naevi and early melanoma, and can estimate molecular alterations directly from standard stained slides.

The work matters because pathology underpins melanoma diagnosis, staging and prognosis, so better tools could refine adjuvant treatment and surveillance decisions. The review stresses that bias, workflow standardisation, interpretability and legal accountability remain unresolved, and that regulation is still evolving, so routine clinical use is not yet established.
limitation: The source is a narrative overview, and it names unresolved issues including dataset bias, lab-to-lab slide workflow standardisation, interpretability and medico-legal accountability that limit routine adoption.
tag: Dual reading
key_points: Deep learning models are reported as comparable to board-certified dermatopathologists, and superior in specific tasks. | Algorithms can predict BRAF mutational status from haematoxylin-eosin-stained slides, acting as virtual biomarkers. | AI may extract morphological and spatial features that the human eye cannot perceive, aiding prognostic stratification. | The EU Artificial Intelligence Act classifies medical AI as high-risk, and regulation is rapidly evolving.
rundown: Surgical pathology is the cornerstone of melanoma diagnosis, staging and prognostic stratification. The review says digital pathology and deep learning are changing this field, with networks trained on large repositories of digitised slides.

Current applications include automated classification of melanocytic lesions. Beyond morphology, algorithms act as virtual biomarkers, predicting molecular changes such as BRAF status and extracting features beyond human perception to stratify prognosis.

Remaining obstacles include dataset bias, inter-laboratory standardisation of whole slide imaging, model interpretability and medico-legal accountability. The EU AI Act treats medical AI as high-risk. The 2024 FDA de novo authorization of DermoSensor reflects wider dermatologic AI progress but does not concern surgical pathology.

The authors expect these tools to augment, not replace, the pathologist's central role in precision oncology, refining adjuvant treatment decisions and surveillance strategies in routine practice.
sources:
- peer_reviewed | La Presse Médicale | https://doi.org/10.1016/j.lpm.2026.104382 | 2026-10-01
prev: 0000000000000000000000000000000000000000000000000000000000000000

sha256

0306368df981278294b24cf17a14678a745829bfc9f7536e5a4dccf90a93ad0c

previous

0000000000000000000000000000000000000000000000000000000000000000